| Lynley Katherine Dornier, | |
|
913 Alfred Street, Scott, LA 70583 | |
| (225) 588-1946 | |
| Not Available |
| Full Name | Lynley Katherine Dornier |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 913 Alfred Street, Scott, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205450871 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 15333 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lynley Katherine Dornier, 2082 Cloverdale Ave, Baton Rouge, LA 70808-2916 Ph: (225) 588-1946 | Lynley Katherine Dornier, 913 Alfred Street, Scott, LA 70583 Ph: (225) 588-1946 |
News Archive
Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.
Inflammatory arthritis is the name for a group of diseases that cause joint pain and swelling. This happens because the body's immune system attacks its own tissues and causes inflammation.
Scientists are reporting an advance toward enabling more blood banks to adopt so-called "extended blood group typing," which increases transfusion safety by better matching donors and recipients. Their report on a new, automated genetic method for determining a broader range of blood types appears in ACS' Analytical Chemistry, a semi-monthly journal.
A new study shows that molecular similarities exist between the 2009 H1N1 influenza virus and other strains of seasonal H1N1 virus that have been circulating in the population since 1988. These results suggest that healthy adults may have a level of protective immune memory that can blunt the severity of infection caused by the 2009 H1N1 influenza virus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
› Verified 1 days ago